One of the most frustrating side effects associated with overall blood glucose control improvement in people with diabetes using intensive insulin therapy is weight gain. The addition of Symlin (pramlintide) to intensive insulin therapy for diabetes treatment improves long-term blood glucose control beyond that obtained with insulin therapy alone and significantly decreases weight gain and risk of hypoglycemia events. Pramlintide (Symlin) is an analogue to the native amylin.
Tag Archives: blood glucose control
Bydureon exenatide or Byetta exenatide are novel GLP-1 (Glucagon-like Peptide-1) incretin mimetic hormone FDA approved for use in type 2 diabetes treatment. Byetta (exenatide) and Bydureon (exenatide) are used in combination therapy to improve blood glucose control in people diagnosed with type 2 diabetes who are taking sulfonylureas, a metformin, a thiazolidinediones (TZDs), a combination of metformin and thiazolidinediones, or a combination of sulfonylureas and metformin.
Sulfonylureas medications for Type 2 diabetes treatment were first type two medications marketed in 1957 for type 2 diabetes treatment. The first generation sulfonylureas which are tolinase, diabinese, and orinase, can improve hyperglycemia but potential drug interactions resulting in hypoglycemia make these type 2 diabetes medications less attractive than the following second generation of sulfonylureas drugs. Glipizide and glyburide drugs were introduced in 1984, with glimepiride followed in 1996.
» Read more